Drug delivery systems to fight cancer

Fundamentals and Applications of Controlled Release Drug Delivery

Volumn , Issue , 2012, Pages 493-516

  Bhardwaj, Vivekanand ^a   Kumar, M N V Ravi ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DOSAGE; TARGETED DRUG DELIVERY;

ACTIVE SUBSTANCE; CANCER CHEMOTHERAPY; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; STATE-OF-THE ART REVIEWS; SYSTEMIC DELIVERIES; TISSUE DISTRIBUTIONS;

CONTROLLED DRUG DELIVERY;

EID: 84884285545     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0881-9_15     Document Type: Chapter

References (73)

1. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818-1822
2. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416
3. Iyer AK et al (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812-818
4. Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409-419
5. Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 17:735-749
6. Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592-599
7. Peer D et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2:751-760
8. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99:392-397
9. Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782
10. Cho K et al (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310-1316
11. Kante B et al (1980) Tissue distribution of [3H]actinomycin D adsorbed on polybutylcya- noacrylate nanoparticles. Int J Pharm 7:45-53
12. Couvreur P, Tulkens P, Roland M (1977) Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett 84:323-326
13. Moghimi SM, Kissel T (2006) Particulate nanomedicines. Adv Drug Deliv Rev 58:1451-1455
14. Hanes J (2006) New polymeric nanomedicines for targeted and controlled drug delivery. Nanomedicine 2:273
15. Alonso MJ (2004) Nanomedicines for overcoming biological barriers. Biomed Pharmacother 58:168-172
16. Duncan R (2005) Nanomedicine gets clinical. Mater Today 8:16-17
17. Florence AT (1997) The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259-266
18. Sakuma S, Hayashi M, Akashi M (2001) Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 47:21-37
19. Mathiowitz E et al (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410-414
20. Desai N et al (2004) Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol. Eur J Cancer Suppl 2:182-183
21. Ruenraroengsak P, Cook JM, Florence AT (2010) Nanosystem drug targeting: facing up to complex realities. J Control Release 141:265-276
22. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160
23. Drummond DC et al (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-744
24. Shapira I et al (2009) Evolving lipid-based delivery systems in the management of neoplastic disease. Oncol Rev 3:113-124
25. Ibrahim NK et al (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044
26. Schnitzer JE (1992) gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol Heart Circ Physiol 262: H246-H254
27. Desai N et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324
28. Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803
29. Vicent MJ, Duncan R (2006) Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 24:39-47
30. Brem H et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012
31. Qiu L et al (2007) Polymeric micelles as nanocarriers for drug delivery. Expert Opin Ther Pat 17:819-830
32. Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agent- incorporating polymer micelles. Cancer Sci 100:572-579
33. Matsumura Y (2008) Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 60:899-914
34. Matsumura Y (2008) Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 38:793-802
35. Torchilin V (2007) Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24:1-16
36. Gelderblom H et al (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598
37. Singh AT et al (2008) A novel nanopolymer based tumor targeted delivery system for paclitaxel. ASCO Meet Abstr 26:11095
38. Yokoyama M (2010) Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 7:145-158
39. Batrakova EV et al (2001) Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 85:1987-1997
40. Venne A et al (1996) Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626-3629
41. Valle J et al (2011) A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting 665 pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 29:1029-1037.
42. Paul A, Vicent MJ, Duncan R (2007) Using small-angle neutron scattering to study the solution conformation of N-(2-Hydroxypropyl)methacrylamide copolymer doxorubicin conjugates. Biomacromolecules 8:1573-1579
43. Duncan R (2009) Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev 61:1131-1148
44. Duncan R et al (2001) Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 74:135-146
45. Li C, Wallace S (2008) Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 60:886-898
46. Seymour LW et al (1987) Effect of molecular weight (Mw) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 21:1341-1358
47. Mita M et al (2009) Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol 64:287-295
48. Schluep T et al (2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci USA 106:11394-11399
49. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221
50. Zhang JA et al (2004) Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270:93-107
51. Rodriguez MA et al (2009) Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer 115:3475-3482
52. Martin EE et al (2010) Vascular targeting by EndoTAG(tm)-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126:1235-1245
53. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424-436
54. Leonard RCF et al (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet(TM)). Breast 18:218-224
55. Reddy LH, Couvreur P (2010) Lipid-based anticancer prodrugs. In: Macromolecular anticancer therapeutics. Springer, New York, pp 291-328
56. Henningsson A et al (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065-4073
57. Jones R et al (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 61:435-441
58. O'Brien S et al (2009) A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML. ASH Annu Meet Abstr 114:1042
59. Nilsson B et al (2009) First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. ASCO Meet Abstr 27:2577
60. Ravel D et al (2008) Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res 14:1258-1265
61. Dubois V et al (2002) CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res 62:2327-2331
62. Trouet A et al (2001) Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res 61:2843-2846
63. Denny WA (2001) Prodrug strategies in cancer therapy. Eur J Med Chem 36:577-595
64. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659-668
65. Bartlett DW et al (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci 104:15549-15554
66. Kawakami K et al (2006) Intratumoral therapy with IL13-PE38 results in effective CTL- mediated suppression of IL-13Ra2-expressing contralateral tumors. Clin Cancer Res 12:4678-4686
67. Ezogelin O et al (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142:69-73
68. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
69. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
70. Weber WA et al (2008) Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5:44-54
71. Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226-243
72. DeNardo SJ (2005) Concluding remarks: tenth conference on cancer therapy with antibodies and immunoconjugates. Clin Cancer Res 11:7201s-7202s
73. Dubowchik GM, Walker MA (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83:67-123